PCM
ABEO icon

Prelude Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Prelude Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-216
Closed -$22K – 1423
2015
Q3 		$22K Buy
+216
New +$28.7K ﹤0.01% 1234

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prelude Capital Management's ABEO Position: Q1 2026 in Review

Prelude Capital Management reduced its Abeona Therapeutics (ABEO) stake by 16% in Q1 2026, selling an estimated $90.5K and leaving 93,073 shares worth $417K. The position accounts for 0.03% of the portfolio, ranked #586.

Prelude Capital Management first reported a position in ABEO in Q2 2015 and has held it in 22 quarters since. The position peaked at $586K in Q4 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Prelude Capital Management held 93,073 shares of Abeona Therapeutics worth $417K as of Q1 2026.
  • Prelude Capital Management sold 18,106 Abeona Therapeutics shares in Q1 2026, an estimated $90.5K.
  • Abeona Therapeutics made up 0.03% of Prelude Capital Management's portfolio in Q1 2026, its #586 holding.
  • Prelude Capital Management first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 22 quarters since.
  • Prelude Capital Management's Abeona Therapeutics position peaked at $586K in Q4 2025.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.